NEW YORK (GenomeWeb) – NeoGenomics today said that it has priced an offering of 7 million shares of common stock at $4.60 per share.

The Ft. Myers, Fla.-based genetic testing services firm expects to raise gross proceeds of $32.2 million from the offering, which is expected to close on Aug. 20. Net proceeds are anticipated at around $30 million.

NeoGenomics said it will use the proceeds from the offering for working capital and general corporate purposes, which could include potential acquisitions and repayment of debt.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: Plasmodium knowlesi population genetics, oral microbiome of infants and children, and more.

The New York Times editorial board weighs in on scientific research misconduct.

The European Commission says it won't take funds from the European Research Council's budget for its new European Fund for Strategic Investment.

The case of the 'devious defecator' examines the protections of the Genetic Information Nondiscrimination Act.